Rosetta Genomics (NASDAQ:ROSG) Stock Rating Lowered by Barrington Research

Barrington Research downgraded shares of Rosetta Genomics (NASDAQ:ROSG) from an outperform rating to a market perform rating in a research note issued to investors on Monday, December 18th, Marketbeat Ratings reports.

Shares of Rosetta Genomics (ROSG) traded down $0.01 during trading on Monday, reaching $0.58. 110,521 shares of the company’s stock were exchanged, compared to its average volume of 115,915. The company has a market capitalization of $3.54, a P/E ratio of -0.06 and a beta of 0.32. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.10 and a quick ratio of 2.10. Rosetta Genomics has a fifty-two week low of $0.48 and a fifty-two week high of $6.96.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at

Rosetta Genomics Company Profile

Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH).

Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with's FREE daily email newsletter.

Leave a Reply